Rasagiline
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Using no skill — this is a direct, fully-specified content-generation task (report template already given verbatim); no coding/debugging/brainstorming applies.
Rasagiline: From Parkinson’s Disease to PLA2G6-Associated Neurodegeneration
One-Sentence Summary
Rasagiline is a selective monoamine oxidase-B (MAO-B) inhibitor originally used for Parkinson’s disease. The TxGNN model predicts it may be effective for PLA2G6-Associated Neurodegeneration, but this direction is currently supported by 0 clinical trials and 0 publications, and the underlying rationale itself flags the link as likely a knowledge-graph artifact rather than a true mechanistic signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson’s disease (referenced in the repurposing rationale; not confirmed via EU license data, as the drug is not marketed in the EU) |
| Predicted New Indication | PLA2G6-Associated Neurodegeneration |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in DrugBank for this evidence pack (flagged as a High-severity data gap). Based on information embedded in the evidence pack’s own repurposing rationales for other candidates, Rasagiline is known to act as an irreversible, selective MAO-B inhibitor, reducing dopamine breakdown and providing antioxidant/neuroprotective effects — the basis for its established use in Parkinson’s disease.
PLA2G6-associated neurodegeneration, however, is a distinct disease entity: a PLA2G6 enzyme defect causing abnormal phospholipid metabolism, leading to infantile neuroaxonal dystrophy through lipid peroxidation and iron accumulation. This pathway has no established overlap with MAO-B–mediated dopamine metabolism or antioxidant signaling.
The evidence pack’s own mechanistic assessment is explicit on this point: the high TxGNN score for this candidate “may reflect a clustering effect among ‘neurodegenerative disease’ nodes in the knowledge graph rather than true mechanistic specificity.” In other words, the score is likely driven by graph-topological proximity between neurodegenerative disease nodes, not a genuine pharmacological rationale — which is why no clinical trials or literature have emerged to support it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EU marketing authorization records found — Rasagiline is currently not marketed under this evidence pack’s regulatory data (0 authorizations on file).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (PLA2G6-associated neurodegeneration) has no supporting clinical trials or literature, and the mechanistic rationale itself is assessed as weak — most likely a knowledge-graph clustering artifact rather than a genuine pharmacological signal. There is no basis to advance this specific indication at this time.
To proceed, the following is needed:
- Confirmed MOA data via DrugBank API (currently a High-severity data gap, DG002)
- TFDA/SmPC-equivalent label warnings and contraindications (currently a Blocking data gap, DG001 — required before any S1 safety screening)
- Preclinical/mechanistic studies directly linking MAO-B inhibition to PLA2G6-related lipid peroxidation/iron-deposition pathways, if this candidate is to be pursued further
Note: Among the 10 predicted indications in this pack, Lewy body dementia (rank 8, L3, “Research Question” stage) shows substantially stronger support — an α-synuclein/MAO-B mechanistic link, exploratory Phase 2 biomarker trials in related dementias, and multiple preclinical papers — and may warrant separate evaluation as a more credible repurposing candidate than the top-ranked prediction discussed above.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.